Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma

The oral tyrosine kinase inhibitors (TKI) sorafenib, regorafenib, and cabozantinib are approved for advanced hepatocellular carcinoma (aHCC) and improve survival. However, patients on these medications frequently require dose reductions or discontinuation due to multiple side effects leading to poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Tin-Yun, Daunov, Katherine, Lee, Richard T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716780/
https://www.ncbi.nlm.nih.gov/pubmed/34976819
http://dx.doi.org/10.3389/fonc.2021.780798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716780/
https://www.ncbi.nlm.nih.gov/pubmed/34976819
http://dx.doi.org/10.3389/fonc.2021.780798

Ejemplares similares